



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/436,184	11/08/1999	JACK R. WANDS	21486-032001US	6241
30623 7590 10/30/2008 MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C ATTN: PATENT INTAKE CUSTOMER NO. 30623 ONE FINANCIAL CENTER BOSTON, MA 02111				
EXAMINER				
CANELLA, KAREN A				
ART UNIT		PAPER NUMBER		
1643				
MAIL DATE		DELIVERY MODE		
10/30/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

09/436,184

Applicant(s)

WANDS ET AL.

Examiner

Karen A. Canella

Art Unit

1643

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 10,13-15,39-50 and 72-76 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 10,13-15,39-50 and 72-76 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/C)
- Paper No(s)/Mail Date 5/15/2008
- 4) ☐ Interview Summary (PTO-413)
- Paper No(s)/Mail Date ____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: ____

DETAILED ACTION

Claims 10, 43, 72, 74 and 76 have been amended. Claims 10, 13-15, 39-50, 72-76 are pending and under consideration.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The rejection of Claims 10, 13-15, 39-50, 72-76 under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement is maintained for reasons of record. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The instant claims have been amended to be dependent upon the coding sequence of SEQ ID NO:3, both of which are human sequences. Applicant has previously provided a declaration by Jack Wands averring that three different anti-sense constructs which fall under the scope of the amended claims reduced HAAH expression and inhibited tumor growth in vivo. This has been considered but not found persuasive. The instant claims are directed to the anti-sense modulation of the human AAH, and read on the inhibition of tumor growth in a human patient by the administration of a nucleic acid vector which transcribes a polynucleotide which is complementary of the HAAH regulatory coding sequence which is not disclosed. In the event that the claims were drawn to encompass a complementary coding region within SEQ ID NO:3, the specification is not enabling for the claims requiring the inhibition of tumor growth in a mammal, which reads on the treatment of a human patient with a naturally occurring tumor for the following reasons.

Anti-sense therapy requires uptake of the administered polynucleotide by the target tumor cells. The specification does not provide dosage or data for administering a therapeutically effective dosage of the complementary sequences of the regulatory regions of SEQ ID NO:3, or

SEQ ID NO:3 itself, to tumor cells which would result in the inhibition of growth, reproduction or survival of cancer cells. It is noted that many anti-sense therapies which appear to be promising using transfection in vitro, fail to provide any therapeutic efficacy when administered in vivo. Dar and Huang (Molecular Pharmaceutics, 2006, Vol. 3, pp. 2805-2809) teach that antisense therapy is hindered by poor stability in physiological fluids and limited intracellular uptake (abstract). In an article published eight years after the year of the instant filing, Sundaram et al (Nucleic Acids Research, 2007, Vol. 35, pp. 4396-4408) teach that despite the conceptual simplicity of the antisense approach, utilization of antisense is impaired by poor cellular entry and rapid degradation (page 579, second column, first full paragraph). Thus it can be concluded from these references that the art is unreliable with respect to in vivo treatment.

Because of all the deficiencies discussed above, and the unreliability in the art, one of skill in the art would be subject to undue experimentation without reasonable expectation of success in order to practice the claimed invention.

Applicant has provided a Declaration under C.F.R. 1.132 to aver that mice transplanted with glioblastoma cells which were previously transfected with the instant anti-sense nucleic acid produced a substantially smaller tumor mass than mice transplanted with glioblastoma cells which were not transfected with the anti-sense construct. this has been considered but not found persuasive because it fails to overcome one of the major hurdles of antisense therapy with regard to tumor uptake as set forth above..

Applicant argues that the specification provides enough information to allow for the dosage and delivery of the nucleic acid in a pharmaceutically effective manner. This has been considered but not found persuasive for the reasons set forth in the rejection above, particularly in regard to the limited intracellular uptake in target tumors.

Applicant has provided the article by Patil et al to support the notion that anti-sense therapy is not an unpredictable art. This article has been considered but not found persuasive because the targeted tissue is the retina which not a tumor and thus issues of tumor uptake and breakdown of the administered nucleic acid by tumor proteases are not complicating factors.

Further, Patil states "The innate ability of DNA-based drugs to be internalized by target cells is minimal under normal circumstances. In addition, poor biological stability and a short half-life result in unpredictable pharmacokinetics. furthermore, DNA molecules that do manage to enter the cell are subsequently subjected to intracellular degradation along with stringently restricted nuclear access". These statements serve to confirm the above rejection. Patil further states that over the past several years many improvements have been made in the DNA delivery systems. However, the instant specification must be enabled as of the filing date of November 8, 1999 and improvements in the art after that date cannot be construed as enabling the instant specification.

All claims are rejected.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen A. Canella whose telephone number is (571)272-0828. The examiner can normally be reached on 10-6:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on (571)272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Karen A Canella/

Primary Examiner, Art Unit 1643